Burkholderia pseudomallei: Difference between revisions
From IDWiki
Burkholderia pseudomallei
m (→) |
m (→) |
||
| (26 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Background== |
|||
= Microbiology = |
|||
*Also called '''melioidosis''' or '''Whitmore's disease''' |
|||
* Oxidase positive, indole-negative Gram-negative rod with "'''safety pin'''" appearance |
|||
* Non-hemolytic |
|||
===Microbiology=== |
|||
= Epidemiology = |
|||
*Oxidase [[Oxidase::positive]], indole [[Indole::negative]] [[Stain::Gram-negative]] [[Shape::bacillus]] with "'''safety pin'''" appearance (i.e. bipolar staining) |
|||
* Humans and animals |
|||
*[[Hemolysis::Non-hemolytic]] |
|||
* Important cause of death in SE Asia and northern Australia |
|||
*Colonies start small, smooth, cream-coloured with a metallic sheen, but become dry and wrinkly after 1 to 2 days of incubation |
|||
** Up to 80% seroprevalence in Thailand, mostly asymptomatic |
|||
*Inherently resistant to [[Polymixin|polymixins]] |
|||
** Sporadic cases elsewhere |
|||
* May have latent disease with reactivation much later |
|||
* Acquired by percutaneous inoculation, inhalation (esp. lab workers), and ingestion |
|||
* Risk factors for clinical disease |
|||
** Diabetes |
|||
** Heavy alcohol use |
|||
** Chronic lung disease |
|||
** Chronic kidney disease |
|||
** Treatment with glucocorticoids |
|||
** Cancer |
|||
** Thalassemia |
|||
===Epidemiology=== |
|||
= Clinical Presentation = |
|||
*Humans and animals |
|||
* Incubation period 9 days (range 1 to 21 days) |
|||
*Important cause of death in south-east Asia and northern Australia |
|||
* Presentations can vary from asymptomatic, skin ulcers, abscesses, latent infection, chronic pneumonia (similar to TB), or fulminant shock |
|||
**Up to 80% seroprevalence in Thailand, mostly asymptomatic |
|||
** Pneumonia (50%) |
|||
**More cases during the rainy season |
|||
** GU infection (15%) |
|||
**Sporadic cases elsewhere, including the Middle East, Africa, and the Americas |
|||
** Skin (15%) |
|||
*May have latent disease with reactivation much later |
|||
** Primary bacteremia (10%) |
|||
*Acquired by percutaneous inoculation, inhalation (esp. lab workers), and ingestion |
|||
** Septic arthritis/OM (3-5%) |
|||
*Risk factors for clinical disease |
|||
** Neuro (3-5%) |
|||
**Diabetes |
|||
* About 20% of clinical cases with develop septic shock |
|||
**Heavy alcohol use |
|||
**Chronic lung disease |
|||
**Chronic kidney disease |
|||
**Treatment with glucocorticoids |
|||
**Cancer |
|||
**Thalassemia |
|||
==Clinical Manifestations== |
|||
= Diagnosis = |
|||
*Incubation period [[Usual incubation period::9 days]] (range [[Incubation period range::1 to 21 days]]) |
|||
* Culture |
|||
*Presentations can vary from asymptomatic, skin ulcers, abscesses, latent infection, chronic pneumonia (similar to TB), or fulminant shock[[CiteRef::diemert2010th]][[CiteRef::meumann2011cl]] |
|||
** Blood, throat, and urine cultures from all patients with suspected melioidosis |
|||
**[[Pneumonia]] (50%) |
|||
** Grows on blood agar, MacConkey, etc. (i.e. ''not'' a fastidious organism) |
|||
**Genitourinary infection (15%) |
|||
** Can use selective colistin or polymyxin B |
|||
**Skin infection (15%), with ulcers, nodules, or abscesses |
|||
** On sheep blood agar, grows as small, smooth, cream-coloured colony with metallic sheen |
|||
**Primary bacteremia (10%) |
|||
** May develop a dry and '''wrinkled''' appearance after 1 to 2 days of incubation</ul> |
|||
**Septic arthritis/OM (3-5%) |
|||
* MALDI-ToF is ''not'' reliable for identifying it |
|||
**Neuro (3-5%) |
|||
* Other methods |
|||
**Disseminated infections can involve liver, spleen, lung, and prostate |
|||
** PCR |
|||
*About 50% of clinical cases have [[Causes::bacteremia]], and 20% of cases will develop [[Causes::septic shock]] |
|||
** Immunofluorescence and latex agglutination |
|||
*Can occasionally lay latent and reactivate decades after exposure |
|||
** Serology (acute/convalescent) |
|||
===Prognosis and Complications=== |
|||
= Management = |
|||
*50% mortality even with high-quality care |
|||
* Intrinsic resistance to many antibiotics, especially using efflux pumps |
|||
* Ceftazidime |
|||
* Amoxicillin-clavulanic acid |
|||
* TMP-SMX |
|||
==Diagnosis== |
|||
= Biosafety = |
|||
*Culture |
|||
* Lab workers can have aerosol exposure |
|||
**Blood, throat, and urine cultures should be taken from ''all'' patients with suspected melioidosis |
|||
* May need prophylaxis in high-risk patients |
|||
**Grows on blood agar, MacConkey, etc. (i.e. ''not'' a fastidious organism) |
|||
** Septra or doxy or amox/clav</ul> |
|||
**Can use selective colistin or polymyxin B, since it is inherently resistant |
|||
* Monitor with serology at baseline, weeks 1 2 4 and 6 post-exposure |
|||
**On sheep blood agar, grows as small, smooth, cream-coloured colony with metallic sheen |
|||
** Needs to be sent to CDC via NML</ul> |
|||
**May develop a dry and '''wrinkled''' appearance after 1 to 2 days of incubation |
|||
*MALDI-ToF may misidentify it as [[Burkholderia thailandensis]], and automated biochemical tests may misidentify it as [[Chromobacterium violaceum]] |
|||
*Other methods |
|||
**PCR |
|||
**Immunofluorescence and latex agglutination |
|||
**Serology (acute/convalescent) |
|||
==Management== |
|||
*Intrinsic resistance to many antibiotics, including [[colistin]], primarily using efflux pumps |
|||
*Treat with induction followed by eradication therapy |
|||
**Induction: [[Is treated by::ceftazidime]], [[Is treated by::imipenem]], or [[Is treated by::meropenem]] for 10-14 days |
|||
**Eradication: [[Is treated by::TMP-SMX]] for 3+ months |
|||
*Others: [[Is treated by::amoxicillin-clavulanic acid]] |
|||
==Prevention== |
|||
===Laboratory Safety=== |
|||
*[[Biosafety risk groups|Biosafety risk group 3]] |
|||
*Lab workers can have aerosol exposure if aerosol-generating procedure done outside of a BSC, bite/scratch from infected lab animals, or needlestick/percutaneous exposure |
|||
**Those at higher risk include: not wearing proper PPE, [[diabetes]], [[chronic liver disease]], [[chronic kidney disease]], [[Alcohol use disorder|alcohol abuse]], chronic [[Corticosteroids|corticosteroid]] use, [[hematologic malignancy]], [[neutropenia]] or neutrophil dysfunction, [[chronic lung disease]], [[thalassemia]], or other [[immunosuppression]] |
|||
*May need prophylaxis in high-risk patients |
|||
**[[TMP-SMX]] or [[doxycycline]] or [[amoxicillin-clavulanic acid]] |
|||
**[[TMP-SMX]] DS 2 tablets (>60 kg) or SS 3 tablets (40-60 kg) or DS 1 tablet (<40 kg) PO bid |
|||
**[[Amoxicillin-clavulanic acid]] 20/5 mg/kg/dose PO tid |
|||
**Duration: 21 days |
|||
*Monitor with serology at baseline, weeks 1 2 4 and 6 post-exposure |
|||
**Needs to be sent to CDC via NML |
|||
{{DISPLAYTITLE:''Burkholderia pseudomallei''}} |
{{DISPLAYTITLE:''Burkholderia pseudomallei''}} |
||
[[Category:Gram-negative bacilli]] |
[[Category:Gram-negative bacilli]] |
||
Latest revision as of 13:36, 25 May 2021
Background
- Also called melioidosis or Whitmore's disease
Microbiology
- Oxidase positive, indole negative Gram-negative bacillus with "safety pin" appearance (i.e. bipolar staining)
- Non-hemolytic
- Colonies start small, smooth, cream-coloured with a metallic sheen, but become dry and wrinkly after 1 to 2 days of incubation
- Inherently resistant to polymixins
Epidemiology
- Humans and animals
- Important cause of death in south-east Asia and northern Australia
- Up to 80% seroprevalence in Thailand, mostly asymptomatic
- More cases during the rainy season
- Sporadic cases elsewhere, including the Middle East, Africa, and the Americas
- May have latent disease with reactivation much later
- Acquired by percutaneous inoculation, inhalation (esp. lab workers), and ingestion
- Risk factors for clinical disease
- Diabetes
- Heavy alcohol use
- Chronic lung disease
- Chronic kidney disease
- Treatment with glucocorticoids
- Cancer
- Thalassemia
Clinical Manifestations
- Incubation period 9 days (range 1 to 21 days)
- Presentations can vary from asymptomatic, skin ulcers, abscesses, latent infection, chronic pneumonia (similar to TB), or fulminant shock12
- Pneumonia (50%)
- Genitourinary infection (15%)
- Skin infection (15%), with ulcers, nodules, or abscesses
- Primary bacteremia (10%)
- Septic arthritis/OM (3-5%)
- Neuro (3-5%)
- Disseminated infections can involve liver, spleen, lung, and prostate
- About 50% of clinical cases have bacteremia, and 20% of cases will develop septic shock
- Can occasionally lay latent and reactivate decades after exposure
Prognosis and Complications
- 50% mortality even with high-quality care
Diagnosis
- Culture
- Blood, throat, and urine cultures should be taken from all patients with suspected melioidosis
- Grows on blood agar, MacConkey, etc. (i.e. not a fastidious organism)
- Can use selective colistin or polymyxin B, since it is inherently resistant
- On sheep blood agar, grows as small, smooth, cream-coloured colony with metallic sheen
- May develop a dry and wrinkled appearance after 1 to 2 days of incubation
- MALDI-ToF may misidentify it as Burkholderia thailandensis, and automated biochemical tests may misidentify it as Chromobacterium violaceum
- Other methods
- PCR
- Immunofluorescence and latex agglutination
- Serology (acute/convalescent)
Management
- Intrinsic resistance to many antibiotics, including colistin, primarily using efflux pumps
- Treat with induction followed by eradication therapy
- Induction: ceftazidime, imipenem, or meropenem for 10-14 days
- Eradication: TMP-SMX for 3+ months
- Others: amoxicillin-clavulanic acid
Prevention
Laboratory Safety
- Biosafety risk group 3
- Lab workers can have aerosol exposure if aerosol-generating procedure done outside of a BSC, bite/scratch from infected lab animals, or needlestick/percutaneous exposure
- Those at higher risk include: not wearing proper PPE, diabetes, chronic liver disease, chronic kidney disease, alcohol abuse, chronic corticosteroid use, hematologic malignancy, neutropenia or neutrophil dysfunction, chronic lung disease, thalassemia, or other immunosuppression
- May need prophylaxis in high-risk patients
- TMP-SMX or doxycycline or amoxicillin-clavulanic acid
- TMP-SMX DS 2 tablets (>60 kg) or SS 3 tablets (40-60 kg) or DS 1 tablet (<40 kg) PO bid
- Amoxicillin-clavulanic acid 20/5 mg/kg/dose PO tid
- Duration: 21 days
- Monitor with serology at baseline, weeks 1 2 4 and 6 post-exposure
- Needs to be sent to CDC via NML
References
- ^ Bart J. Currie, Linda Ward, Allen C. Cheng. David Joseph Diemert. The Epidemiology and Clinical Spectrum of Melioidosis: 540 Cases from the 20 Year Darwin Prospective Study. PLoS Neglected Tropical Diseases. 2010;4(11):e900. doi:10.1371/journal.pntd.0000900.
- ^ E. M. Meumann, A. C. Cheng, L. Ward, B. J. Currie. Clinical Features and Epidemiology of Melioidosis Pneumonia: Results From a 21-Year Study and Review of the Literature. Clinical Infectious Diseases. 2011;54(3):362-369. doi:10.1093/cid/cir808.
